Orthocell Sells 100 Units of Nerve Repair Product in US

MT Newswires Live
2025/12/18

Orthocell (ASX:OCC) said it sold 100 units of its Remplir nerve repair product in the US, according to a Thursday Australian bourse filing.

This follows 61 active submissions to US hospital Value Analysis Committees, with 17 approvals secured ahead of schedule and additional approvals anticipated in fiscal 2026, the filing said. The first 4,000 units of Remplir have been shipped from Australia and warehoused in the US.

Orthocell's shares fell past 2% in recent trading on Thursday.

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10